Document:

Exhibit 10.1

 

VOTING
AGREEMENT

 

This VOTING
AGREEMENT (this “Agreement”) is entered into as of September 24, 2020, by and between Metuchen
Pharmaceuticals LLC, a Delaware limited liability company (“Company”), and the undersigned (the
 “Stockholder”).

 

WHEREAS, as of the date
hereof, the Stockholder is the sole record and beneficial owner of and has the sole power to vote (or to direct the voting of)
the number of shares of common stock, par value $0.0001 per share (the “Common Shares”) of Neurotrope, Inc.
a Nevada corporation (“Neurotrope”), set forth opposite the Stockholder’s name on Schedule I hereto
(such Common Shares together with any other shares of Neurotrope (“Shares”));

 

WHEREAS, Petros Pharmaceuticals,
Inc., a Delaware corporation (“Parent”), PM Merger Sub 1, LLC, a Delaware limited liability company and direct
wholly owned subsidiary of Parent (“Merger Sub 1”), PN Merger Sub 2, Inc., a Delaware corporation and direct
wholly owned subsidiary of Parent (“Merger Sub 2”), Company and Neurotrope, have previously entered into an
agreement and plan of merger, dated as of May 17, 2020 (as amended from time to time, the “Merger Agreement”),
pursuant to which (i) Merger Sub 1 will be merged with and into the Company (the “Metuchen Merger”) with the
Company continuing as the surviving limited liability company and as a wholly owned subsidiary of Parent, and (ii) Merger Sub 2
will be merged with and into Neurotrope (the “Neurotrope Merger” and together with the Metuchen Merger, the
 “Mergers”) with Neurotrope continuing as the surviving corporation and as a wholly owned subsidiary of Parent;

 

WHEREAS, the Neurotrope
Merger requires the affirmative vote of the holders of (i) a majority in voting power of the outstanding shares of Neurotrope Common
Stock (as defined in the Merger Agreement) voting separately as a class and (ii) two-thirds in voting power of the outstanding
shares of Neurotrope Preferred Stock (as defined in the Merger Agreement) voting separately as a class, in each case, on the applicable
record date;

 

WHEREAS, as an inducement
to Company’s willingness to consummate the transactions contemplated by the Merger Agreement, transactions from which the
Stockholder believes it will derive substantial benefits through its ownership interest in Neurotrope, the Stockholder is entering
into this Agreement.

 

NOW, THEREFORE, in consideration
of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, the parties agree as
follows:

  

ARTICLE
I 

DEFINITIONS

 

Section
1.1 Capitalized Terms. For purposes of this Agreement, capitalized terms used and not defined herein shall have the
respective meanings ascribed to them in the Merger Agreement.

 

ARTICLE
II 

VOTING AGREEMENT 

 

Section
2.1 Agreement to Vote. The Stockholder hereby agrees that, during the Voting Period (as defined below), and at any
duly called meeting of the stockholders of Neurotrope (or any adjournment or postponement thereof), or in any other circumstances
(including action by written consent of stockholders in lieu of a meeting) upon which a vote, adoption or other approval or consent
with respect to the adoption of the Merger Agreement or the approval of the Neurotrope Merger and any of the transactions contemplated
thereby is sought, the Stockholder shall, if a meeting is held, appear at the meeting, in person or by proxy, and shall provide
a written consent or vote (or cause to be voted), in person or by proxy, all Shares held by the Stockholder as of any applicable
record date (the “Subject Shares”), in each case (a) in favor of (i) any proposal to adopt and approve or reapprove
the Merger Agreement and the other transactions contemplated thereby and (ii) waiving any notice that may have been or may be
required relating to the Neurotrope Merger or any of the other transactions contemplated by the Merger Agreement, and (b) against
any Acquisition Proposal and any action in furtherance of any such Acquisition Proposal. As used herein, (x) the term “Expiration
Time” shall mean the earliest to occur of (A) the Effective Time and (B) the date and time of the valid termination
of the Merger Agreement in accordance with its terms, and (y) the term “Voting Period” shall mean such period
of time between the date hereof and the Expiration Time.

 

      

     

    

 

ARTICLE
III 

TERMINATION

 

Section
3.1 Termination. This Agreement shall automatically terminate, and neither Company nor the Stockholder shall have
any rights or obligations hereunder and this Agreement shall become null and void and have no effect upon the earliest to occur
of: (a) the Effective Time; or (b) the valid termination of the Merger Agreement in accordance with its terms. The parties acknowledge
that, upon termination of this Agreement as permitted under and in accordance with the terms of this Article III, no party
to this Agreement shall have the right to recover any claim with respect to any losses suffered by such party in connection with
such termination, except that the termination of this Agreement shall not relieve either party to this Agreement from liability
for such party’s intentional and material breach of any terms of this Agreement. Notwithstanding anything to the contrary
herein, the provisions of this Article III and Article IV shall survive the termination of this Agreement.

 

ARTICLE
IV 

MISCELLANEOUS

 

Section
4.1 Further Actions. Subject to the terms and conditions set forth in this Agreement,
the Stockholder agrees to take any and all actions and to do all things reasonably necessary
to effectuate this Agreement.

 

Section
4.2 Fees and Expenses. Except as otherwise specifically provided herein, each party shall bear its own expenses in
connection with this Agreement and the transactions contemplated hereby.

 

Section
4.3 Amendments, Waivers, etc. This Agreement may not be amended except
by an instrument in writing signed by the parties hereto and specifically referencing this Agreement. The failure of any party
to assert any rights or remedies shall not constitute a waiver of such rights or remedies.

 

Section
4.4 Notices. Any notice, request, instruction or other document required to be given hereunder shall be sufficient
if in writing, and sent by confirmed electronic mail transmission of a “portable document format” (“.pdf”)
attachment (provided that any notice received by electronic mail transmission or otherwise at the addressee’s location on
any business day after 5:00 p.m. (addressee’s local time) shall be deemed to have been received at 9:00 a.m. (addressee’s
local time) on the next business day), by reliable overnight delivery service (with proof of service), or hand delivery, addressed
as follows:

 

If to Company, to:

 

Metuchen Pharmaceuticals LLC 

c/o Juggernaut Capital Partners 

5301 Wisconsin Avenue NW, Suite 570 

Washington, DC 20015 

Attn: John Shulman

Email: jshulman@juggernautcap.com

 

with a copy to (which shall not
constitute notice):

 

Morgan, Lewis & Bockius LLP 

1111 Pennsylvania Avenue, NW 

Washington, DC 20004 

Attn: Andrew M. Ray

Email: andrew.ray@morganlewis.com

 

If to the Stockholder, to the address or electronic mail address
set forth on the signature pages hereto, or to such other person or address as any party shall specify by written notice so given.

 

      

     

    

 

Section
4.5 Headings. Headings of the Articles and Sections of this Agreement are for convenience of the parties only and
shall be given no substantive or interpretive effect whatsoever.

 

Section
4.6 Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability
of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement,
or the application of such provision to any person or any circumstance, is invalid or unenforceable (a) a suitable and equitable
provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of
such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision to other
persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability
affect the validity or enforceability of such provision, or the application of such provision, in any other jurisdiction.

 

Section
4.7 Entire Agreement; Assignment. This Agreement constitutes the entire agreement, and supersedes all other prior
agreements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter hereof.
Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto
(whether by operation of law or otherwise) without the prior written consent of the other parties, except that without consent,
Company may assign all or any of its rights and obligations hereunder to any of its Affiliates that assume the rights and obligations
of Company under the Merger Agreement. Subject to the preceding two sentences, this Agreement will be binding upon, inure to the
benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns. Notwithstanding anything
to the contrary set forth herein, the Stockholder agrees that this Agreement and the obligations hereunder shall be binding upon
any Person to which record or beneficial ownership of the Stockholder’s Subject Shares shall pass, whether by operation or
law or otherwise, including the Stockholder’s heirs, guardians, administrators or successors and assigns, and the Stockholder
agrees to take all actions necessary to effect the foregoing.

 

Section
4.8 Governing Law. THIS AGREEMENT AND ALL QUESTIONS RELATING TO THE INTERPRETATION OR ENFORCEMENT OF THIS AGREEMENT
SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAW
OF THE STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF TO THE EXTENT THAT SUCH PRINCIPLES WOULD DIRECT
A MATTER TO ANOTHER JURISDICTION.

 

Section
4.9 Specific Performance. The Stockholder acknowledges that any breach of this
Agreement would give rise to irreparable harm for which monetary damages would not be an adequate remedy and each of Company and
Neurotrope shall be entitled to a decree of specific performance and to temporary, preliminary and permanent injunctive relief
to prevent breaches or threatened breaches of any of the provisions of this Agreement, without the necessity of proving the inadequacy
of monetary damages as a remedy, which shall be the sole and exclusive remedy for any such breach.

 

Section
4.10 Submission to Jurisdiction. The parties hereby irrevocably submit to the exclusive personal jurisdiction of
the state and federal courts sitting in the City of New York, Borough of Manhattan, and hereby waive, and agree not to assert,
as a defense in any action, suit or proceeding for the interpretation or enforcement hereof, that it is not subject thereto or
that such action, suit or proceeding may not be brought or is not maintainable in said courts or that the venue thereof may not
be appropriate or that this Agreement may not be enforced in or by such courts, and the parties hereto irrevocably agree that all
claims relating to such action, suit or proceeding shall be heard and determined in such courts. The parties hereby consent to
and grant any such court jurisdiction over the person of such parties and, to the extent permitted by law, over the subject matter
of such dispute and agree that mailing of process or other papers in connection with any such action or proceeding in the manner
provided in Section 4.4 or in such other manner as may be permitted by Legal Requirements shall be valid and sufficient
service thereof.

 

      

     

    

 

Section
4.11 Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT
IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES
ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING
TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i) NO REPRESENTATIVE,
AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER,
(iii) EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (iv) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 4.11.

 

Section
4.12 Counterparts. This Agreement may be executed in two or more counterparts (including by facsimile transmission
or other means of electronic transmission, such as by electronic mail in “.pdf” form), each of which shall be an original,
with the same effect as if the signatures thereto and hereto were upon the same instrument, and shall become effective when one
or more counterparts have been signed by each of the parties and delivered (by facsimile or otherwise) to the other parties. 

 

[Remainder of page left intentionally
blank. Signature pages follow.]

 

      

     

    

 

IN WITNESS WHEREOF, Company and the Stockholder
have caused this Agreement to be duly executed as of the day and year first above written.

 

	 	METUCHEN PHARMACEUTICALS, LLC
	 	 	 
	 	By:  	 
	 	 	Name: 	                  
	 	 	Title: 	 

 

[Signature Page to Voting Agreement]

 

	 	 
	 	[Stockholder]
	 	 
	 	Address: [●]
	 	 
	 	 
	 	 
	 	Email Address: [●]

 

[Signature Page to Voting Agreement]

 

      

     

    

 

Schedule I

Ownership of Common Shares

 

	Name and Address of Stockholder	Number of Common Shares
	[                                ]	[            ]Exhibit 10.2

 

WARRANT AMENDMENT AGREEMENT

 

This Warrant Amendment
Agreement (this “Agreement”), dated as of September __, 2020, is by and between Neurotrope, Inc.,
a Nevada corporation (the “Company”), and the undersigned holder (the “Holder”) of Series E
warrants to purchase shares of the Company’s common stock, $0.0001 par value (the “Common Stock”).

 

WHEREAS, the Holder
beneficially owns Series E warrants to purchase shares of Common Stock at an exercise price of $32.00 per share that were
issued in November 2015, as set forth on the Holder's signature page hereto (the “Original Warrants”).

 

WHEREAS, the Company
and the Holders desire to amend and restate the Original Warrants to (a) reduce the exercise price thereof from $32.00 to
$25.00 per share, (b) extend the Expiration Date of the Original Warrants to either (i) the five year anniversary of
the closing of the mergers contemplated by the Merger Agreement (as defined below), or (ii) if the Merger Agreement is terminated
or the mergers contemplated thereby have not been consummated, the one year anniversary of the Expiration Date set forth in the
Original Warrants, and (c) revise the Original Warrants to provide that in the event of a spin-off (the “Spin-Off”)
of Neurotrope Bioscience, Inc. or any other entity or entities containing the existing business of the Company (collectively,
the “Spin-Off Company”), the Holder shall only receive, in lieu of any other consideration, warrants, in the
form attached hereto as Exhibit A (the "Spin-Off Warrants"), to purchase a number of shares of Spin-Off
Company based on the same ratio as the ratio used to determine the number of shares of common stock of Spin-Off Company that common
stockholders of the Company will receive in the Spin-Off, as more fully described in the following WHEREAS clause. The initial
exercise price of the Spin-Off Warrants will be determined by dividing $250 million by the number of shares of common stock of
Spin-Off Company outstanding immediately after the Spin-Off, excluding any shares issued in connection with a financing of Spin-off
Company after the date hereof. As used herein "Merger Agreement" means that certain Agreement and Plan of Merger
and Reorganization dated as of May 17, 2020 among the Company, Petros Pharmaceuticals, Inc., PM Merger Sub 1, LLC, PN
Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC (the "Original Merger Agreement"), as such Original Merger
Agreement may be (i) amended from time to time or have any provision thereof waived from time to time, in each case that results
in the stockholders of the Company owning 49% or more of the outstanding common stock of the combined company at the closing of
the mergers contemplated by such Merger Agreement and is not, and is not reasonably expected to be, otherwise detrimental to the
Holder, or (ii) in the event of an amendment or waiver that does not meet the standards of (i) above, is amended from
time to time or have any provision thereof waived from time to time, in each case with the prior written consent of holders of
a majority of the Series E Warrants who have signed this Agreement or agreements substantially similar to this Agreement.

 

WHEREAS, the number
of shares of common stock underlying the Spin-Off Warrants shall be determined by using the same ratio used to determine how many
shares of Spin-Off Company that the common stockholders of the Company will receive in the Spin-Off, it being contemplated as of
the date of this Agreement that the Spin-Off will result in each common stockholder of the Company receiving one share of the Spin-Off
Company for every five shares of the Company owned by such stockholder (the “Spin-Off Ratio”).  Although
the Spin-Off Ratio may change depending on a number of factors, the number of shares of common stock of the Spin-Off Company underlying
the Spin-Off Warrants will be based on the final Spin-Off Ratio.  In other words, assuming that the final Spin-Off Ratio is
the same as the currently contemplated Spin-Off Ratio, the Spin-Off Warrants will be exercisable for one share of Spin-Off
Company for every five shares of Company Common Stock underlying your Original Warrants.  If the Spin-Off Ratio changes
after the date of this Agreement, so will the ratio applicable to the Spin-Off Warrants.

  

    1

     

    

 

WHEREAS, pursuant to
Section 9 of the Original Warrants, the Original Warrants may be modified or amended or the provisions thereof waived with
the written consent of the Company and the Holder.

  

NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for good and valuable consideration the receipt and adequacy
of which are hereby acknowledged, the Holder and the Company hereby agree as follows:

 

1. Amendment
and Restatement of the Original Warrants. The Company and the Holder hereby consent and agree to the amendment and restatement
of the Original Warrants in the form attached hereto as Exhibit B, which shall supersede and replace the Original Warrants
in their entirety.

 

2. Registration.
The Company shall use its commercially reasonable efforts to have declared effective a registration statement under the Securities
Act of 1933, as amended (the “Securities Act”) of Spin-Off Company permitting the sale of the shares underlying
the Spin-Off Warrants at the time of the Spin-Off or as soon thereafter as is practicable.

 

3. Spin-Off
Warrants. The Company agrees to cause the Spin-Off Company to issue to the Holder upon consummation of the Spin-Off, the Spin-Off
Warrants exercisable for the number of shares and at the exercise price determined as provided in the preceding WHEREAS clauses.
The Company and the Holder hereby acknowledge and agree that there can be no assurance that the Spin-Off shall occur, but the amendments
to the Original Warrants pursuant to this Agreement shall be effective regardless.

 

4. Representations
and Warranties of the Company. The Company hereby makes the representations and warranties set forth below to the Holder that
as of the date of its execution of this Agreement.

 

(a) Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement
by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action
on the part of such Company and no further action is required by such Company, its board of directors or its stockholders in connection
therewith. This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.

 

(b) Organization.
The Company is a duly organized and validly existing corporation in good standing under the laws of the State of Nevada.

 

(c) No Conflicts.
The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions
contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate or
articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien upon any
of the properties or assets of the Company, or give to others any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument
(evidencing Company debt or otherwise) or other material understanding to which the Company is a party or by which any property
or asset of the Company is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation,
order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject
(including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected.

 

    2

     

    

  

(d) Disclosure.
All of the disclosure furnished by or on behalf of the Company to the Holder regarding the Company and its Subsidiaries, their
respective businesses and the transactions contemplated hereby, including but not limited to the disclosure set forth in the SEC
Reports, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. As used
herein, “SEC Reports” means all reports, schedules, forms, statements and other documents required to be filed
by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the reporting requirements
of the Securities Exchange Act of 1934, as amended (the "1934 Act"), including all exhibits included therein and
financial statements, notes and schedules thereto and documents incorporated by reference therein.

 

(e) No Integrated
Offering. None of the Company, its Subsidiaries or any of their affiliates, nor any Person acting on their behalf has, directly
or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would
require approval of shareholders of the Company for purposes of any applicable shareholder approval provisions, including, without
limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of
the Company are listed or designated for quotation. None of the Company, its Subsidiaries, their affiliates nor any Person acting
on their behalf will take any action or steps that would cause the offering of any of the Securities to be integrated with other
offerings for purposes of any such applicable shareholder approval provisions.

 

(f) No Disqualification
Events. With respect to Securities to be offered and sold hereunder in reliance on Rule 506(b) under the 1933 Act,
none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company
participating in the offering hereunder, any beneficial owner of 20% or more of the Company's outstanding voting equity securities,
calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the 1933 Act) connected
with the Company in any capacity at the time of sale (each, an "Issuer Covered Person" and, together, "Issuer
Covered Persons") is subject to any of the "Bad Actor" disqualifications described in Rule 506(d)(1)(i) to
(viii) under the 1933 Act (a "Disqualification Event"), except for a Disqualification Event covered by Rule 506(d)(2) or
(d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished
to the Holder a copy of any disclosures provided thereunder.

 

5.            Representations
and Warranties of the Holder. The Holder hereby makes the representations and warranties set forth below to the Company that
as of the date of its execution of this Agreement.

 

(a)            Due
Authorization. The Holder represents and warrants that (i) the execution and delivery of this Agreement by it and the
consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on its behalf and
(ii) this Agreement has been duly executed and delivered by the Holder and constitutes the valid and binding obligation of
the Holder, enforceable against it in accordance with its terms except (i) as limited by general equitable principles and
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other
equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law..

 

(b)            Ownership
of Original Warrants. The Holder is the sole legal and beneficial owner of the Original Warrants, and has good, valid and marketable
title and interest (legal and beneficial) to the Original Warrants free and clear of any lien, encumbrance, pledge, charge, security
interest, mortgage, option, equity or other adverse claim, and has not (a) assigned, transferred, hypothecated, pledged or
otherwise disposed of the Original Warrants or its ownership rights in the Original Warrants, or (b) given any person or entity
any transfer order, power of attorney or other authority of any nature whatsoever with respect to the Original Warrants. The Holder
agrees to indemnify the Company for any breach of the foregoing representation.

 

    3

     

    

  

(c)            Holder
Status. The Holder represents and warrants that is an “accredited investor” as defined in Rule 501 under the
Securities Act.

 

6. Disclosure of
Transactions and Other Material Information. The Company shall file a current report on Form 8-K on or before 8:30 a.m.,
New York City time, on September [   ]1,
2020, describing the terms of the transactions contemplated by this Agreement, all in the form required by the 1934 Act and attaching
the form of this Agreement (and all schedules and exhibits thereto not otherwise attached), as exhibits to such filing (including
all attachments, the "8 K Filing"). As of immediately following the filing of the 8-K Filing with the Commission,
the Holder shall not be in possession of any material, nonpublic information received from the Company, any of its Subsidiaries
or any of their respective officers, directors, employees, affiliates or agents, that is not disclosed in the 8-K Filing or in
prior filings with the Commission. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees
that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any
of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, on the one hand, and the Holder
or any of its affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and
confirms that the Holder will rely on the foregoing in effecting transactions in securities of the Company. The Company shall not,
and shall cause its Subsidiaries and its and each of their respective officers, directors, employees, affiliates and agents, not
to, provide the Holder with any material, nonpublic information regarding the Company or any of its Subsidiaries from and after
the date hereof without the express prior written consent of the Holder. To the extent that the Company, its Subsidiaries or any
of its or their respective officers, directors, employees, affiliates or agents delivers any material, non-public information to
the Holder without the Holder's prior written consent, the Company hereby covenants and agrees that the Holder shall not have any
duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates
or agents with respect to, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees,
affiliates or agents not to trade on the basis of, such material, non-public information.

 

7. Most Favored
Nation. The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof
for a period of at least 90 days from the date hereof that none of the terms offered to any Person relating to the amendment of
the Original Warrants (or any amendment, modification, waiver or release thereof) (each an "Amendment Document"),
is or will be more favorable to such Person than those of the Holder and this Agreement. If, and whenever on or after the date
hereof, the Company enters into an Amendment Document with terms that are materially different from this Agreement, then (i) the
Company shall provide written notice thereof to the Holder promptly following the occurrence thereof and (ii) the terms and
conditions of this Agreement shall be, without any further action by the Holder or the Company, automatically amended and modified
in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and/or
conditions (as the case may be) set forth in such Amendment Document, provided that upon written notice to the Company at any time
the Holder may elect not to accept the benefit of any such amended or modified term or condition, in which event the term or condition
contained in this Agreement shall apply to the Holder as it was in effect immediately prior to such amendment or modification as
if such amendment or modification never occurred with respect to the Holder. The provisions of this paragraph shall apply similarly
and equally to each Amendment Document.

 

 

1
Insert the Trading Day immediately following the date of execution of this Agreement.

 

    4

     

    

 

8. Governing
Law. This Agreement shall be governed by and construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Agreement shall be governed by, the laws of the State of New York, except for
its conflicts of law provisions.

 

9. Effectiveness
of Agreement; Prohibition on Certain Amendments to Merger Agreement. This Warrant Amendment will not become effective until
countersigned by the Holder and the Company and the Company will need the approval of Metuchen Pharmaceuticals LLC prior to such
execution. The Company hereby covenants and agrees that it will not, without the prior written consent of holders of a majority
of the Series E Warrants who have signed this Agreement or agreements substantially similar to this Agreement, allow any amendment
to the Original Merger Agreement or any waiver to the Original Merger Agreement that (i) causes the stockholders of the Company
to own less than 49% of the outstanding common stock of the combined company at the closing of the mergers contemplated by the
Merger Agreement, or (ii) results in such amended or waived Original Merger Agreement to be, or is reasonably expected to
be, more detrimental than the Original Merger Agreement to the holders of Series E Warrants that have signed this Agreement
or agreements substantially similar to this Agreement.

 

10. Counterparts.
This Agreement may be executed in the original or by facsimile in two or more counterparts, each of which shall be deemed an original
and all of which, taken together, shall constitute but one and the same instrument.

 

[Remainder of page intentionally
left blank.]

 

    5

     

    

  

IN WITNESS WHEREOF, the undersigned
have executed this Agreement as of the date first written above.

 

 

COMPANY:

 

 

NEUROTROPE, INC.

 

 

	By:	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
	 	 	 
	WARRANT HOLDER:	 
	 	 	 
	[NAME OF WARRANT HOLDER]	 
	 	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

 

 

Number of Original Warrants held:

 

    6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]